Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Novo Nordisk is slimming down its name to "Novo" as part of a sweeping cultural overhaul aimed at regaining ground in the red-hot obesity drug market. The rebrand comes alongside a new cultural strategy called "The Novo Way," built on four pillars: customer obsession, competitiveness, clarity, and care and integrity. The move signals urgency as the company battles Eli Lilly, pipeline setbacks, and a nearly 15% drop in its share price this year.
Novo Nordisk is officially going by "Novo" in its day-to-day operations — a name change that's more than cosmetic. The Danish pharma giant unveiled a new cultural strategy called "The Novo Way," anchored by four principles: customer obsession, competitiveness, clarity, and care and integrity. The company will retain "Novo Nordisk A/S" as its legal name, and is set to share more details on its broader business strategy at a Capital Markets Day on September 21.
The rebrand comes at a pivotal — and pressured — moment. Novo is locked in a fierce rivalry with Eli Lilly in the obesity drug space, and while its oral GLP-1 is outpacing Lilly by hundreds of thousands of U.S. prescriptions per week, commercial wins have been overshadowed by pipeline stumbles. Last week, the company scrapped two late-stage trials for its experimental heart drug ziltivekimab, adding to investor anxiety.
By the Numbers:
Why it matters: A rebrand alone won't win the obesity drug war, but it signals that Novo is taking stock of its competitive position and pushing for internal transformation. With a Capital Markets Day looming, all eyes are on whether the strategy behind the new name can match the ambition.
